HOUSE_OVERSIGHT_025890.jpg
3.12 MB
Extraction Summary
7
People
10
Organizations
1
Locations
3
Events
2
Relationships
3
Quotes
Document Information
Type:
News article / press release compilation
File Size:
3.12 MB
Summary
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
People (7)
| Name | Role | Context |
|---|---|---|
| Leonard Schleifer | Chief Executive and Founder, Regeneron |
Quoted discussing drug pricing, accessibility, and the ODYSSEY trial.
|
| Mark Schoenebaum | Pharmaceutical Analyst, Evercore ISI |
Commented on investor disappointment regarding FDA approval breadth.
|
| Geoffrey Porges | Biotechnology Analyst, Sanford C. Bernstein |
Published a survey regarding physician prescribing habits; projected $4.8 billion sales.
|
| Brennan | Executive, CVS Caremark |
Discussed restrictions and medical record requirements for Praluent.
|
| Nissen | Cardiologist, Cleveland Clinic |
Discussing statin intolerance and conducting trials for Amgen/Pfizer.
|
| Olivier Brandicourt | Chief Executive Officer, Sanofi |
Quoted regarding the Sanofi/Regeneron alliance and cardiovascular heritage.
|
| Donald Trump | Subject of Headline |
Mentioned in the 'Trending on LinkedIn' headline, though the body text is unrelated.
|
Organizations (10)
| Name | Type | Context |
|---|---|---|
| Regeneron | Pharmaceutical Company |
Developer of Praluent.
|
| Evercore ISI | Investment Bank |
Provided price forecasts.
|
| Sanford C. Bernstein | Investment Bank |
Employer of analyst Geoffrey Porges.
|
| CVS Caremark | Pharmacy Benefit Manager |
Discussing coverage restrictions.
|
| Sanofi | Pharmaceutical Company |
Alliance partner with Regeneron.
|
| Cleveland Clinic | Medical Center |
Employer of Dr. Nissen.
|
| Amgen | Pharmaceutical Company |
Competitor conducting trials.
|
| Pfizer | Pharmaceutical Company |
Competitor developing similar drug.
|
| FDA | Government Agency |
Regulatory body approving the drug.
|
| House Oversight Committee | Government Body |
Source of the document (Footer).
|
Timeline (3 events)
Locations (1)
| Location | Context |
|---|---|
|
Market for the drug.
|
Relationships (2)
Sanofi and Regeneron alliance mentioned in text.
Described as 'Evercore ISI’s pharmaceutical analyst'.
Key Quotes (3)
"We don’t want the noise about these drugs to be price. We have to make sure that people get access to the drug for a fair price if they’re insured, for free if they’re not insured, or at a discount if they’re under-insured."Source
— Leonard Schleifer
HOUSE_OVERSIGHT_025890.jpg
Quote #1
"Dehspite significant progress over the last decades, high cholesterol remains a leading concern in the U.S. and globally..."Source
— Olivier Brandicourt
HOUSE_OVERSIGHT_025890.jpg
Quote #2
"We’re not trying to replace statins"Source
— Leonard Schleifer
HOUSE_OVERSIGHT_025890.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document